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Abstract: Rheumatoid Arthritis (RA) is an incurable autoimmune disease that promotes the chronic
impairment of patients’ mobility. For this reason, it is vital to develop therapies that target early
inflammatory symptoms and act before permanent articular damage. The present study offers
two novel therapies based in advanced drug delivery systems for RA treatment: encapsulated
chondroitin sulfate modified poly(amidoamine) dendrimer nanoparticles (NPs) covalently bonded
to monoclonal anti-TNF α antibody in both Tyramine-Gellan Gum and Tyramine-Gellan Gum/Silk
Fibroin hydrogels. Using pro-inflammatory THP-1 (i.e., human monocytic cell line), the therapy
was tested in an inflammation in vitro model under both static and dynamic conditions. Firstly, we
demonstrated effective NP-antibody functionalization and TNF-α capture. Upon encapsulation, the
NPs were released steadily over 21 days. Moreover, in static conditions, the approaches presented
good anti-inflammatory activity over time, enabling the retainment of a high percentage of TNF
α. To mimic the physiological conditions of the human body, the hydrogels were evaluated in a
dual-chamber bioreactor. Dynamic in vitro studies showed absent cytotoxicity in THP-1 cells and a
significant reduction of TNF-α in suspension over 14 days for both hydrogels. Thus, the developed
approach showed potential for use as personalized medicine to obtain better therapeutic outcomes
and decreased adverse effects.
Keywords: dendrimers; nanocomposite hydrogels; therapeutic efficacy; static conditions; dynamic
conditions; bioreactor
1. Introduction
Inflammatory arthritis is a term used to classify a group of conditions such as rheuma-
toid arthritis (RA), which affects the immune system and causes pain, stiffness, and joint
damage [1,2]. Different therapeutic strategies for decreasing the pain and improving the
outcomes of both joint damage and disability caused by RA have rapidly advanced in the
past few years.
TNF α has an important role in the pathogenesis of RA, since it is overexpressed in
the synovial joints of patients [3]. Therefore, anti-TNF α monoclonal antibody therapies
have been pursued to target TNF α and treat RA. These therapies have been effective
in most treated RA patients. However, there is a percentage of patients that either fail
to respond to the therapy or experience adverse effects from it [4]. Traditional drugs
including non-steroidal inflammatory drugs (NSAIDs), glucocorticoids (GCs), disease
modifying anti-rheumatic drugs (DMARDs) and biological agents can relieve the pain and
control inflammation [5]. However, current treatments are not fully effective and frequently
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involve high dosage or repeated administration in order to have a therapeutic effect, which
can result in a decrease in overall efficacy and patient compliance and cause severe side
effects [6]. Thus, to overcome existing limitations, new and advanced therapies designed
to tackle inflammatory arthritis are strongly required [7,8].
Nanotechnology, as nanoparticle-based delivery systems, provides a unique series
of advantages for the development of delivery systems including high loading capacity,
controlled release, prolonged circulation, and target delivery [9]. Even so, these systems
have demonstrated unpredictable drug release depending on their polymer structure,
production conditions, and particle size [10]. In order to tune drug release, nanoparticles
have been combined with different biomaterials [11–14]. Amongst the studied biomaterials,
hydrogels appear to demonstrate the most attractive outcomes. Hydrogels are a particularly
appealing type of delivery system. In fact, they can provide the controlled release of
nanoparticles over time, offer controllable degradability, and have the capacity to protect
loaded drugs from degradation [15,16].
Despite being relatively simple and effective, is has been challenging to translate
such approaches into clinical settings. One of the reasons for this may be a reliance on
the settings selected for their study. Current in vitro cellular methods, applied in several
areas of drug discovery, comprise the use of static conditions which do not emulate the
dynamic natural physiological environment found in the human body, thereby failing to
produce reliable data [17,18]. Thus, new dynamic methods need to be established to more
precisely assess the effectiveness of drugs in in vivo systems. Bioartificial devices, as flow
bioreactors, are highly promising tools for tissue engineering and regenerative medicine
applications [19]. They can be used for cell culture, therapeutic approaches, and for in vitro
organ modeling, offering a more physiologically appropriate environment compared to
traditional static conditions [20,21]. Current works have shown that the use of bioreactors
to maintain the culture of cell-laden scaffolds enables the proper flow of nutrients and
increased the diffusion of oxygen through the 3D structures, thereby mimicking specific
aspects of native tissues [21,22].
In previous works, Tyramine-Gellan Gum (Ty-GG) hydrogels [23] and Tyramine-
Gellan Gum/Silk Fibroin (Ty-GG/SF) hydrogels [24] showed good resistance to degrada-
tion, high mechanical strength, and a suitable drug controlled release for treating inflam-
matory conditions such as RA. Monoclonal anti-TNF α antibody (anti-TNF α Ab) linked to
chondroitin sulfate (CS) modified poly(amidoamine) (CS/PAMAM) dendrimer nanoparti-
cles (NPs) were developed and demonstrated a more targeted and effective therapeutic
effect for the management of RA [25]. Herein, with the aforementioned in mind, it was
hypothesized that by combining the two approaches, an improved delivery system would
be achieved with a sustained release that would last for longer periods. For so, a system
based on anti-TNF α Ab-CS/PAMAM dendrimer NPs loaded into Ty-GG and Ty-GG/ SF
hydrogels was developed as a promising drug delivery vehicle with improved therapeutic
efficacy for the treatment of RA. The evaluation of the developed system was performed in
a human monocytic cell line (THP-1)-based inflammation in vitro model under both static
and dynamic culture conditions.
2. Materials and Methods
2.1. Anti-TNF α Ab-CS/PAMAM Dendrimer NPs
2.1.1. Functionalization
Mouse monoclonal antibody [2C8] (26,000 g mol−1) (ab8348, Abcam, Cambridge, UK)
was linked to CS/PAMAM dendrimer NPs previously produced by the authors [25]. The
linkage was obtained through a typical carbodiimide chemistry reaction. Briefly, a 2 g L−1
solution of CS/PAMAM in 19.52 g L−1 of 2-N-Morpholinoethanesulfonic acid hydrate
(MES) (Sigma-Aldrich, St. Louis, MO, USA) was mixed with N-(3-Dimethylaminopropyl)-
N′-ethylcarbodiimide hydrochloride (EDC) (Sigma-Aldrich, St. Louis, MO, USA) (4 equiva-
lents) and NHS sulfo-NHS N-Hydroxysulfosuccinimide sodium salt ≥98% (HPLC) (Sigma-
Aldrich, St. Louis, MO, USA) (two equivalents) for 15 min. At the same time, 20 equivalents
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of anti-TNF α Ab were added with EDC (four equivalents) and were stirred for 15 min.
Then, a CS/PAMAM dendrimer NPs mixture was added to the anti-TNF α mAb mixture
and stirred for 24 h. Upon this time, the solution was dialyzed against distilled water for
48 h. Anti-TNF α Ab-CS/ PAMAM dendrimer NPs were obtained by freezing the solution
at −80 ◦C and freeze-drying (Telstar-LyoAlfa 10/15) up to 48 h.
2.1.2. Evaluation of Anti-TNF α Ab Conjugation Efficacy and Retention of
Biological Activity
The efficacy of the modification was assessed by fluorescence spectrometer FP-8500
(Jasco, Oklahoma City, OK, USA). For that, anti-TNF α Ab-CS/PAMAM dendrimer NPs
and CS/PAMAM dendrimer NPs were allowed to react with a secondary antibody Alexa
Fluor 488 rabbit anti-mouse lgG (H + L) (Molecular Probes, Eugene, OR, USA) in PBS
solution (1:1000) for 1 h. Then, the solutions were analyzed in the fluorescence spectrometer.
The capacity of anti-TNF α Ab-CS/PAMAM dendrimer NPs to capture TNF α was also
evaluated. For the evaluation, modified dendrimers were incubated with 1000 pg mL−1 of
TNF α (Peprotech, London, UK) for 4 h at room temperature. As controls, non-modified
dendrimers were also incubated. After the time of reaction, the solutions were centrifuged,
and the supernatants were kept at −80 ◦C for further analysis. The concentration of free
TNF-α in the supernatant samples was determined using a Human TNF-alpha DuoSET
ELISA kit (R&D Systems, Minneapolis, MN, USA) and a DuoSet Ancillary Reagent Kit 2
(R&D Systems, Minneapolis, MN, USA), following the manufacturer’s instructions. The
samples were measured at an optical density of 450 nm using a microplate reader (Synergy
HT, BIO-TEK, Winooski, VT, USA). Absorbance values were converted into concentrations
using a standard curve of TNF-α in the range of 0 to 1000 pg mL−1.
2.1.3. Production of Anti-TNF α Ab-CS/PAMAM Dendrimer NPs Loaded Ty-GG and
Ty-GG/SF Hydrogels
Ty-GG previously produced by the authors [23] was used to obtain the investigated
hydrogels. With respect to the Ty-GG/SF hydrogels, silk fibroin [24] was extracted from
silkworm cocoons (Portuguese Association of Parents and Friends of Mentally Disabled Cit-
izens (APPACDM, Castelo Branco, Portugal)). Briefly, the cocoons were cut into fragments
and boiled for 30 min in a 0.02 M Sodium carbonate solution (Laborspirit, Loures, Portugal)
to remove sericin. Boiled silkworm cocoons were washed with distilled water and dried
at 70 ◦C. The dry silkworm cocoons were then dissolved in the oven with 9.3 M Lithium
bromide (Laborspirit, Loures, Portugal) for 4 h at 70 ◦C. The dissolved solution was dia-
lyzed using a dialysis tubing, benzoylated (Laborspirit, Loures, Portugal) for 48 h against
distilled water, in order to remove LiBr. Silk fibroin was kept at 4 ◦C until further use.
To prepare the hydrogels, first a solution of horseradish peroxidase (HRP)
(0.84 mg mL−1) (Sigma-Aldrich, St. Louis, MO, USA) in PBS and a solution of hydrogen
peroxide (H2O2) (0.36% (v/v)) (VWR, Radnor, PA, USA) in distilled water were prepared.
Then, 1% Ty-GG solution (w/v) was prepared in distilled water and used for the prepara-
tion of Ty-GG hydrogels and Ty-GG/SF hydrogels. To obtain the Ty-GG/SF hydrogels, 1%
(w/v) of Ty-GG solution was mixed with 2% (w/v) SF (1:1) solution. At this point, anti-TNF
α Ab-CS/PAMAM dendrimer NPs were mixed in the Ty-GG and Ty-GG/SF solutions at a
final concentration of 0.5 mg mL−1. Then, two different crosslinking levels were tested by
adding different amounts of HRP and H2O2 solutions to Ty-GG and Ty-GG/SF solutions,
hereafter denominated C1, C2, C3, and C4, as described in Table 1. Each condition without
anti-TNF α Ab-CS/PAMAM dendrimer NPs were used as control (hereafter designated
C1 CTRL, C2 CTRL, C3 CTRL, and C4 CTRL). Then, the mixtures were transferred into
polypropylene molds and incubate at 37 ◦C until complete gelation.
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C1 167 µL - 97 µL 16.6 µL 10.83 µL
C2 167 µL - 100 µL 18.3 µL 15 µL
C3 83.5 µL 83.5 µL 97 µL 16.6 µL 10.83 µL
C4 83.5 µL 83.5 µL 100 µL 20 µL 13.3 µL
2.1.4. Distribution of FITC-CS/PAMAM Dendrimer NPs throughout Ty-GG and
Ty-GG/SF Hydrogels
To assess the distribution profile of CS/PAMAM dendrimer NPs within Ty-GG and Ty-
GG/SF hydrogels, the nanoparticles were labelled with Fluorescein isothiocyanate (FITC)
(Sigma-Aldrich, St. Louis, MO, USA). Initially, 10 mg mL−1 of CS/PAMAM dendrimer
NPs solution was prepared in a carbonate-bicarbonate coupled buffer (pH 9.2). Then, 50 µL
of 10 mg mL−1 of FITC in anhydrous dimethyl sulfoxide (DMSO) (VWR, Radnor, PA, USA)
solution was added per each mL of CS/PAMAM dendrimer NPs solution under agitation
and kept in the dark at 4 ◦C for 8 h. In the end, the FITC-labelled CS/PAMAM dendrimer
NPs were dialyzed in ultrapure water for 48 h and freeze-dried. Then, FITC-CS/PAMAM
dendrimer NPs, at a final concentration of 0.1 mg mL−1, were mixed with Ty-GG and Ty-
GG/SF solutions and HRP and H2O2 solutions (as described in Table 1). After crosslinking,
the hydrogels were immersed in PBS and kept in a water bath at 37 ◦C for 24 h to remove
free FITC. The hydrogels were observed under a confocal microscope (Leica TCS SP8).
2.1.5. Release Profile of Anti-TNF α Ab-CS/PAMAM Dendrimer NPs from Ty-GG and
Ty-GG/SF Hydrogels
To evaluate the release profile of anti-TNF α Ab-CS/PAMAM dendrimer NPs, each
release system developed, C1, C2, C3, and C4 (more details in Table 1), were immersed
in PBS at 37 ◦C. After 3 h, 24 h, 72 h, 168 h, 336 h, and 504 h, the PBS solution which
was in contact with hydrogels was collected to an Eppendorf 1.5 mL and kept at −80 ◦C
until further analysis. To formulate the calibration curve, anti-TNF α Ab-CS/PAMAM
dendrimer NPs dilutions were prepared ranging from 0 mg mL−1 to 0.5 mg mL−1. The
UV absorbance of dendrimers NPs was read at 280 nm in a microplate reader to quantify
the anti-TNF α Ab-CS/PAMAM dendrimer release (EMax; Molecular Devices, Sunnyvale,
CA, USA). Three samples per condition were evaluated at each time point. The absorbance
values were converted into concentrations using the calibration curve.
2.2. THP-1 Cells-Based Inflammation In Vitro Model: Static Conditions
2.2.1. Cell Culture
The Human monocytic cell line (THP-1) (SIGMA, USA) was expanded in RPMI 1640
Medium, GlutaMAX™ Supplement, HEPES (Thermo Fisher Scientific, Waltham, MA,
USA), supplemented with 10% fetal bovine serum (PAA; Pasching, Austria) and 1% (v/v)
of penicillin and streptomycin (Gibco, Life Technologies, Grand Island, NY, USA), under
standard culture conditions (i.e., at 37 ◦C in a humidified atmosphere containing 5 vol%
CO2). When ≈80% confluence was reached, cells were trypsinized and seeded in a well
of a 24-well plate at a density of 5 × 105 cells per well. For induction of THP-1 cells’
differentiation into macrophages, cells were cultured under RPMI with 100 nM phorbol 12-
myristate-13-acetate (PMA) (Sigma-Aldrich, St. Louis, MO, USA), hereafter designated as
healthy cells. After 24 h, the medium was replaced with a RPMI medium without PMA and
incubated for another 48 h. At this point, to develop an inflammation in vitro model, cells
were incubated with 100 ng mL−1 of Lipopolysaccharide (LPS) (Sigma-Aldrich, St. Louis,
MO, USA) in an RPMI medium and incubated for 5 h to induce an inflammatory response.
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Cells under LPS stimulation were incubated with each release system developed,
C1, C2, C3, and C4 (more details in Table 1), respective controls (C1 CTRL, C2 CTRL, C3
CTRL, and C4 CTRL) and 0.5 mg mL−1 anti-TNF α Ab-CS/PAMAM dendrimer NPs. Only
cells under LPS stimulation were studied (hereafter designated as LPS stimulation). Cells’
metabolic activity and proliferation were monitored along seven days of culture. The TNF
α neutralization was assessed along 14 days of culture.
2.2.2. Cells’ Metabolic Activity
Cells’ metabolic activity was evaluated on days one, three, and seven of culture with
Alamar Blue at each time point. For this, an RPMI culture medium containing 10% (v/v) of
Alamar Blue® (BioRad, Oxford, UK) was added to the different conditions.
The culture plates were kept in the dark, at 37 ◦C in the CO2 incubator for 4 h.
Afterward, 100 µL of each well were transferred in triplicate to 96-well plates. The fluo-
rescence was read at an excitation wavelength of 530/25 nm and an emission wavelength
of 590/535 nm, using a microplate reader (Synergy HT, BioTek, Instruments, Winooski,
VT, USA).
2.2.3. Cells’ Proliferation
The proliferation of the THP-1 cells at days one, three, and seven of culture was
analyzed by dsDNA quantification. At each timepoint, cells were washed with PBS solution
and lysed with ultrapure water. The cells’ lysate solution was placed into 1.5 mL microtubes
and then stored at −80 ◦C for further analysis. The Quanti-IT PicoGreen dsDNA Assay Kit
(Alfagene, Lisboa, Portugal) was used to quantify dsDNA, accordingly with manufacturers’
instructions. Briefly, 28.7 µL of each sample was mixed with 71.3 µL of PicoGreen solution
and 100 µL 1X TE buffer in a well of a 96-well white microplate. Then, the plate was
incubated in the dark for 10 min and the fluorescence was read using an excitation of
480/20 nm and an emission of 528/20 nm in a microplate reader. DNA concentration was
determined using a standard curve in the range of 2 to 0 µL mL−1.
2.2.4. Assessment of TNF α Neutralization
The neutralization of TNF α as evaluated at one, three, seven and fourteen days of
culture. At these time-points, the medium of each condition was recovered and stored at
−80 ◦C. To determine the levels of TNF α captured, the TNF-α concentration in the samples
was measured using the Human TNF-alpha DuoSET ELISA kit and the DuoSet Ancillary
Reagent Kit 2, following manufacturers’ instruction. The optical density was measured
at 450 nm using the microplate reader and the values were converted into concentration
using a TNF-α calibration curve ranging from 1000 to 0 pg mL−1.
2.3. THP-1 Cells-Based Inflammation In Vitro Model: Dynamic Conditions
2.3.1. Cell Culture in a Dual-Chamber Bioreactor
THP-1 cells were seeded at a density of 5 × 105 cells/well in TCP coverslips in 24-well
plates. As conducted under static conditions, for induction of THP-1 cell differentiation,
cells were cultured under RPMI with 100 nM PMA. After 24 h, the medium was replaced
with RPMI medium without PMA and incubated for another 48 h. Then, the cells were
incubated with 100 ng mL−1 of LPS in an RPMI medium and incubated for 5 h to induce
an inflammatory response. After LPS stimulation, the coverslips were transferred to the
lower chamber of a dual-chamber bioreactor [26] with an RPMI medium contained LPS
and the therapeutic effect of developed release systems was evaluated.
2.3.2. Therapeutic Effect of Developed Release Systems
To evaluate the therapeutic effect of the developed approaches under dynamic condi-
tions, one condition of each delivery system was selected and added to the cells cultured on
the lower chamber of the bioreactor. Then, the entire piping system was assembled and the
syringes were filled with medium and connected to the syringe pump. The dual-chamber
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bioreactor was kept at 37 ◦C in a humidified 5% CO2 atmosphere and the compartment con-
taining the cells and hydrogels was perfused at a rate of 12.5 µL h−1. After one, three, seven,
and fourteen days of perfusion, the culture medium contained in the collection tubes was
removed and stored at−80 ◦C to analyze of the amount of TNF α present through an ELISA
assay, as described above. Delivery systems cultured in THP-1 cell-based inflammation
in vitro models under standard static conditions were used as control.
2.4. Statistical Analysis
Statistical analysis was performed by GraphPad Prism 8 version, (GraphPad Software
Inc, San Diego, CA, USA) where a Shapiro–Wilk normality test was previously made to
evaluate the data normality. Statistical significances were obtained as * p < 0.05. All assays
were triplicated and the results were presented as mean ± standard deviation.
3. Results and Discussion
The present work is focused on the development of anti-TNF α Ab-CS/PAMAM
dendrimer NPs loaded into Ty-GG and Ty-GG/ SF hydrogels as a promising delivery
system. This way, hydrogels would increase the controlled and sustained release of
anti-TNF α Ab-CS/PAMAM dendrimer NPs at the target site, improving their therapeutic
efficacy while requiring less frequent administrations [15]. With this in mind, the developed
NPs loaded-hydrogels were evaluated in a THP-1 cells-based inflammation in vitro model
(Figure S1) under static standard conditions and dynamic conditions using a bioreactor.
3.1. Evaluation of Anti-TNF α Ab Conjugation and TNF α Sequestration Efficacy
Free antibodies have been reported to present the capacity to neutralize the target
agent, TNF α [27]. Herein, we aimed to investigate the biological activity of anti-TNF α
conjugated CS/PAMAM dendrimer NPs in vitro. A monoclonal anti-TNF α antibody was
linked to CS/PAMAM dendrimer NPs and the efficacy of the linking reaction, as well
as the preservation of its biological activity (i.e., its ability to capture TNF α) were evalu-
ated (Figure 1). Fluorescence spectroscopy was used to assess the success of conjugation
(Figure 1a) with both previous conjugation of the CS/PAMAM dendrimer NPs (both with
and without linked Ab) and a secondary antibody labeled with Alexa Fluor 488 dye. The
intensity of the emission spectra of Alexa 488 between 500 and 600 nm for the anti-TNF
α Ab-CS/PAMAM dendrimer NPs was significantly higher ('3500) than CS/PAMAM
dendrimer NPs without anti-TNF α Ab ('800). Therefore, the conjugation of CS/PAMAM
dendrimer NPs with the anti-TNF α Ab was successfully achieved, despite the fact that
some unspecific secondary Ab binding was observed (as expected).
To further assess the anti-TNF α Ab-CS/PAMAM dendrimer NPs’ effectiveness in
TNF α sequestering, the difference between the initial and the final amount of free TNF α
in solution was quantified following the dendrimer NPs’ addition (Figure 1b). The data
showed that after 4 h of incubation, the degree of capture was 56.8%. This demonstrates
that the immobilization process did not compromise the biological activity of the anti-TNF
α Ab, as demonstrated by the retention of its capacity to capture TNF α.
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Figure 1. Anti-TNF α antibody conjugation to CS/PAMAM dendrimer NPs. (a) Fluorescence
spectroscopy of CS/PAMAM dendrimer NPs and anti-TNF α Ab-CS/PAMAM dendrimer NPs. (b)
Percentage of TNF α captured by anti-TNF α Ab-CS/PAMAM dendrimer NPs. Data shown as
Mean ± SD.
3.2. Production of Anti-TNF α Ab-CS/PAMAM Dendrimer NPs Loaded-Ty-GG and Ty-GG/SF
Hydrogels: Dendrimer NPs Distribution and Release Profile
At this point, anti-TNF α Ab-CS/PAMAM dendrimer NPs were loaded into Ty-GG
and Ty-GG/SF disc hydrogels (Figure 2). The gelation of Ty-GG and Ty-GG/SF solutions
within polypropylene molds produced discs with similar sizes. However, it was clear that
the addition of SF resulted in more opaque hydrogels (Figure 2a). To assess the distribution
of dendrimer NPs throughout the hydrogels, they were labelled with FITC and observed
using confocal microscopy (Figure 2b). It was possible to observe that CS/PAMAM
dendrimers NPs were uniformly dispersed across the hydrogel network, exhibiting low
aggregation as expected (since the encapsulation of NPs in hydrogels reduces particles’
aggregation) [28]. This dispersion uniformity guarantees a larger exposure of the surface
of the nanoparticle and, consequently, better performance as a therapeutic agent [29].
Considering the success of the hydrogel-based NPs’ encapsulation, it was critical to
optimize Ty-GG and Ty-GG/SF hydrogels’ crosslinking levels to maximize anti-TNF α
Ab-CS/PAMAM dendrimer NPs (Figure 3). Thus, anti-TNF α Ab-CS/PAMAM dendrimer
NPs’ release profile from hydrogels network was assessed over time. Ty-GG hydrogels,
denominated C1 (more details at Table 1), released 73.65% ± 1.85% of the NP’s, while the
same hydrogels but with higher amounts of crosslinking (C2) released 67.12% ± 4.03%,
over 21 days. A similar profile was observed for Ty-GG/SF hydrogels; C3 condition
released 88.13% ± 2.36%, while the condition with higher crosslinking levels, C4, released
67.28% ± 1.47% of the encapsulated NPs over 21 days. When analyzing the conditions
with lower levels of crosslinking (C1 and C3), Ty-GG/SF hydrogels showed a faster release
when compared to Ty-GG hydrogels. However, when comparing the conditions with
higher crosslinking levels (i.e., C2 and C4) no statistical differences were observed among
the conditions. These conditions presented a slower release of the dendrimer NPs with
the increase of crosslinking level, possibly due the contraction of the hydrogel mesh. In
this sense, C2 and C4 showed a more suitable drug release profile when compared to C1
and C3. The slower drug release profile may allow a longer therapy to the patient and,
consequently, a less frequent administration, thereby reducing the side effects caused by
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drug overdose. Noteworthy, none of the conditions reached a maximum drug release
after 21 days of evaluation. Considering the results obtained, it was possible to verify that
hydrogels can be fine-tuned to present a controlled drug release profile over time. This
can allow a prolonged therapeutic effect of anti-TNF α Ab. In this line of reasoning, less
frequent administration of drugs would be necessary and would improve the quality of
life of patients.
Figure 2. Anti-TNF α Ab-CS/PAMAM dendrimer NPs loaded-Ty-GG and Ty-GG/SF hydro-
gels. (a) Representative images of Ty-GG hydrogels and Ty-GG/SF hydrogels. Scale bar: 10 cm.
(b) Schematic representation of FITC-CS/PAMAM dendrimer NPs and FITC-CS/PAMAM dendrimer
NPs loaded-Ty-GG and Ty-GG/SF hydrogels. Scale bar: 5 µm. (c) Representative fluorescence image
of FITC-CS/PAMAM dendrimer NPs distributed within Ty-GG and Ty-GG/SF hydrogels, showing
the NPs in green.
Figure 3. Release profile of anti-TNF α Ab-CS/ PAMAM dendrimer NPs. Release profile of anti-TNF
α Ab-CS/ PAMAM dendrimer NPs from Ty-GG (C1 and C2) and Ty-GG/SF hydrogels (C3 and C4)
with different crosslinking levels after 3, 24, 48, 72, 168, 336, and 504 h. Data shown as Mean ± SD.
* indicates significant differences when comparing C3 and C4 at time point 504 h.
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3.3. Evaluation of Anti-TNF α Ab-CS/ PAMAM Dendrimer NPs Loaded-Ty-GG and Ty-GG/SF
Hydrogels Effects on THP-1 Cells-Based Inflammation In Vitro Models: Static Conditions
In RA, there is a disproportion between pro-inflammatory and anti-inflammatory
cytokines, resulting in a more pronounced pro-inflammatory phenotype [30–33]. For this
reason, most therapies developed to decrease inflammation by inhibiting pro-inflammatory
cytokines are evaluated using cell inflammation in vitro models [7,34]. For this reason,
the influence of the different conditions of anti-TNF α Ab-CS/ PAMAM dendrimer NPs
loaded-Ty-GG (C1 and C2) and Ty-GG/SF (C3 and C4) hydrogels were evaluated using
an inflammation in vitro model created by the induction of THP-1 cells. Ty-GG and Ty-
GG/SF hydrogels without dendrimer NPs (C1 CTRL, C2 CTRL, C3 CTRL, and C4 CTRL)
and dendrimer NPs were used as controls. First, the effect of loaded hydrogels on LPS
stimulated THP-1 cells’ metabolic activity and proliferation was quantified for seven days
using Alamar blue and DNA quantification assays, respectively (Figure 4). From day one
up to day seven, THP-1 cells, under all of the different conditions of Ty-GG and Ty-GG/SF
hydrogels, were shown to be metabolically active over time. Hydrogels missing dendrimer
NPs represent the only instance wherein there was higher metabolic activity at the first
time point (24 h) when compared with the LPS stimulated cells. The enhanced metabolic
activity which was observed can be explained by the increase of energy necessary for the
internalization of dendrimers. In fact, considering the conditions that contained dendrimer
NPs, they were released in a controlled and sustainable way from the hydrogels. While in
this condition, dendrimer NPs were easily accessible, being internalized at a higher rate.
At three and seven days, there was an increase of metabolic activity in all conditions; no
statistical differences were observed among the various conditions.
DNA quantification was used to assess THP-1 cells’ proliferation under different
conditions. At day one, cell proliferation was decreased in C1, C2, C3, and C4 CTRL as
compared to the LPS stimulated cells. However, this effect dissipated over seven days,
with no final differences among the conditions. The lack of influence of the GG hydrogels
and dendrimer nanoparticles over cell viability has been previously known for over a
decade [35,36].
Overall, the results of metabolic activity and cell proliferation analysis provided
evidence regarding the safety of these materials for biomedical applications.
In order to evaluate the capturing efficacy of TNF α by C1, C2, C3, and C4, the level of
free TNF α in the culture medium along 14 days of culture was quantified (Figure 5). Again,
C1 CTRL, C2 CTTRL, C3 CTRL, C4 CTRL, and dendrimer NPs were analyzed. Although at
the beginning of culture only C1 and C2 showed significant differences from their respective
controls in the neutralization of free TNF α, after 14 days all the conditions (C1, C2, C3, and
C4) were shown to significantly neutralize free TNF α. The neutralization levels at day 14
were also significantly different from day one for all the studied conditions. Furthermore,
the results are in agreement with those obtained from the drug release studies. C1 and C3
(lower amount of crosslinking) showed a faster release profile. Moreover, the degree of
TNF α capture was higher compared to C2 and C4 (i.e., higher amounts of crosslinking)
where the release profile was slower and, therefore, the degree of neutralization was lower.
Free dendrimer NPs neutralized higher amounts of TNF α comparing with controls since
day one, as expected, reaching its maximum at day seven similarly to the sequestration
achieved by the anti-TNF α Ab-CS/PAMAM dendrimer NPs. However, at day 14, levels
of free TNF α abruptly increased using free dendrimer NPs, while NPs-loaded hydrogels
retained their capacity to neutralize TNF α. Noteworthy, dendrimer NPs at day 14 showed
levels of free TNF α similar to the controls, corroborating dendrimer NPs’ low long-term
effect. These results showcase the advantages of NP-loaded hydrogels in drug delivery
to chronic diseases, such as RA, considering the prolonged and continuous effect of the
therapy. Hence, this approach may allow the reduction of side effects, providing a better
quality of life to the patient. These data showed the potential of Gellan Gum and SF as
drug delivery systems and corroborates other previous studies [37,38].
Pharmaceutics 2021, 13, 1111 10 of 14
Figure 4. Evaluation of anti-TNF α Ab-CS/ PAMAM dendrimer NPs loaded-Ty-GG and Ty-GG/SF
hydrogels effects on cells metabolic activity and proliferation. (a) THP-1 cells’ metabolic activity
upon culture with anti-TNF α Ab-CS/ PAMAM dendrimer NPs loaded-Ty-GG (C1 and C2) and
Ty-GG/SF (C3 and C4) hydrogels and controls for 1 day of culture. (* indicates significant differences
when comparing Dendrimer NPs with LPS stimulation at time point 1 day); and (b) THP-1 cells’
proliferation by DNA quantification of THP-1 cells upon culture with anti-TNF α Ab-CS/ PAMAM
dendrimer NPs loaded-Ty-GG (C1 and C2) and Ty-GG/SF (C3 and C4) hydrogels and controls for
1 day of culture. (η indicates significant differences when comparing with LPS stimulation. @ indicates
significant differences when comparing with respective CTRL). Data shown as Mean ± SD.
Figure 5. Quantification of TNF α free in the culture medium along 14 days of culture. Results were
normalized by the TNF α values obtained in cultures stimulated by LPS. Data shown as Mean ± SD.
* indicates significant differences when comparing with respective CTRL. Φ indicates significant dif-
ferences when comparing with Dendrimer NPs at each time-point. δ indicates significant differences
when comparing with day one.
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3.4. Evaluation of Anti-TNF α Ab-CS/ PAMAM Dendrimer NPs Loaded-Ty-GG and Ty-GG/SF
Hydrogels Effects on THP-1 Cell-Based Inflammation In Vitro Models: Dynamic Conditions
A dual-chamber bioreactor was used to mimic the dynamic physiological environment
found in the human cartilage and obtain more reliable data concerning the challenges faced
by the drug delivery system. Conditions that led to faster and slower NPs release were
chosen for this setup. C3 was the condition that presented higher NPs release levels and a
better ability to decrease free TNF α. Since C3 is a Ty-GG/SF hydrogel-based strategy and
C2 and C4 were conditions with similarly slow-release profiles, C2 was chosen (considering
it is based on a Ty-GG hydrogel). Therefore, anti-TNF α Ab-CS/ PAMAM dendrimer NPs
loaded-Ty-GG and Ty-GG/SF hydrogels were tested for 14 days using a THP-1 cell-based
inflammation in vitro model under dynamic conditions (Figure 6). The control comprised
THP-1 cell-based inflammation in vitro models under standard static conditions.
Figure 6. Evaluation of anti-TNF α Ab-CS/ PAMAM dendrimer NPs loaded-Ty-GG and Ty-GG/SF
hydrogels effects under dynamic conditions. (a) Representative images of Dynamic culture of
THP-1 cell-based inflammation in vitro model using a dual-chamber bioreactor showing the (I)
dual-chamber bioreactor connected to a syringe pump; (II) higher amplification of the bioreactor
inserted in a 6-well plate showing the piping tubes and collector tubes; and (III) enlarged image of
the dual-chamber bioreactor where it is possible to see the upper and lower chamber. (b) Amount
of TNF α present in the medium, in contact with C2 and C3 in static and dynamic conditions. Data
shown as Mean ± SD. * indicates significant differences when comparing dynamic conditions with
static conditions, Φ indicates significant differences when comparing with day 1.
It was possible to verify that the TNF α concentration present in the supernatant
medium significantly decreased along the 14 days of culture under both dynamic and
control conditions. However, under static conditions, C2 was the only one presenting no
differences to the control, in accordance with the previously release profile evaluation.
Firstly, analyzing the results obtained for static and dynamic conditions, it was observed
that the concentration of TNF α was always lower in dynamic conditions. However, in
dynamic conditions, on day 14, the levels of free TNF α decreased abruptly, indicating that
all anti-TNF α Ab-CS/ PAMAM dendrimer NPs were released from the hydrogels. Under
static conditions, a less accentuated decrease of TNF α was observed, indicating a slower
release of dendrimer NPs over time. Noteworthy, no significant differences were observed
between the dendrimer NP-loaded hydrogels tested.
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4. Conclusions
In this study, an improved system based on anti-TNF α Ab-CS/PAMAM dendrimer
NPs loaded into Ty-GG and Ty-GG/SF hydrogels to tackle inflammatory diseases such as
RA was developed. The produced anti-TNF α Ab- CS/PAMAM dendrimer NPs demon-
strated a capacity to maintain Ab biological activity, enabling a high immobilization degree
of TNF α. Furthermore, it was possible to fine-tune anti-TNF α Ab-CS/PAMAM den-
drimer NP-loaded Ty-GG and Ty-GG/SF hydrogels by altering crosslinking levels, thereby
enabling the control of the dendrimer NPs release profile over time. The in vitro stud-
ies conducted using the THP-1 cell-based inflammation model under static conditions
demonstrated that cells cultured with the developed dendrimer NPs-loaded hydrogels
were metabolically active and proliferative along the culture time. When their capacity
to capture TNF α was evaluated, it was observed that developed systems retained their
capacity to neutralize TNF α even after 14 days. Finally, dynamic studies performed
with the THP-1 cell-based inflammation model showed that the dendrimer NP-loaded
hydrogels maintained an even higher therapeutic effect over time as compared with the
static studies, demonstrating the importance of using a physiologically mimetic environ-
ment. These relevant results support the successful use of these drug delivery systems in
several inflammatory diseases, including RA, in in vivo settings. Overall, the developed
approaches which make use of bioengineered nanoparticle-loaded hydrogels can fill the
current gaps concerning traditional therapies, providing a more targeted and thus more
effective treatment while enabling less frequent administration and, thus, reducing the side
effects caused by an overdosing of drugs.
The developed approach showed potential to be used as personalized medicine
to obtain better therapeutic outcomes and decreased adverse effects. Thus, in the near
future, it is expected that the knowledge acquired in the tissue engineering field can be an
important tool in the development of clinical medicine.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/pharmaceutics13081111/s1, Figure S1. Amount of free TNF α in medium in THP-1 cells
culture without LPS stimulation, designated healthy cells, and with LPS stimulation after 1 day,
confirming the successful development of THP-1 cells-based inflammation in vitro model.
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